Claims for Patent: 9,090,700

Summary for Patent: 9,090,700

Title:	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Abstract:	The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.
Inventor(s):	Friess; Thomas (Diessen-Dettenhofen, DE), Hasmann; Max (Munich, DE), Scheuer; Werner (Penzberg, DE)
Assignee:	Hoffmann-La Roche Inc. (Little Falls, NJ)
Application Number:	12/947,264
Patent Claims:	1. A combined therapy method of treating a breast cancer disease in a patient who has failed prior therapy with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody and an anti-VEGF antibody, wherein the breast cancer disease is characterized by an overexpression of the HER2 receptor protein, and wherein said method demonstrates tumor regression. 2. The method of claim 1, wherein the patient is human. 3. The method of claim 2, wherein the anti-VEGF antibody is bevacizumab. 4. The method of claim 2 wherein the anti-HER2 antibody is trastuzurmab. 5. A method of reducing metastasis of a breast cancer that was non-responsive to prior therapy with an anti-VEGF antibody in a patient, comprising administering to the patient effective amounts of an anti-VEGF antibody and an anti-HER2 antibody, whereby the co-administration of the anti-VEGF antibody and the anti-HER2 antibody effectively reduces metastasis, as quantified by real-time PCR, and wherein the cancer is characterized by an overexpression of the HER2 receptor protein. 6. The method of claim 5, wherein the patient is human. 7. The method of claim 6, wherein the anti-VEGF antibody is bevacizumab. 8. The method of claim 6, wherein the anti-HER2 antibody is trastuzumab. 9. The method of claim 5, wherein the reduction of metastasis is in lung metastasis.

Details for Patent 9,090,700

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2026-03-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2026-03-22
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-03-22
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2026-03-22